Table 4.
Treatments and Outcomes of Patients With COVID-19
| No (%) | |||||
|---|---|---|---|---|---|
| Treatment | Total | Mild (n = 19) | Severe (n = 18) | Crtitical (n = 13) | P Value |
| Antiviral therapy | 50 (100) | 19 (100) | 18 (100) | 13 (100) | - |
| Antibiotic therapy | 36 (72) | 6 (31.6) | 17 (94.4) | 13 (100) | <.001 |
| Use of corticosteroid | 34 (68) | 6 (31.6) | 15 (83.3) | 13 (100) | <.001 |
| Use of gamma globulin | 34 (68) | 10 (52.6) | 12 (70.6) | 12 (92.3) | .060 |
| Immunomodulatory therapy | 44 (88) | 17 (89.5) | 16 (88.9) | 11 (84.6) | 1.000 |
| Cough and sputum treatment | 44 (88) | 16 (84.2) | 16 (88.9) | 12 (92.3) | .872 |
| Chinese patent medicine therapy | 20 (40) | 0 (0) | 12 (66.7) | 8 (61.5) | <.001 |
| Prognosis | |||||
| Hospitalization | 1 (2) | 0 (0) | 0 (0) | 1 (7.7) | .260 |
| Discharge | 42 (84) | 19 (100) | 18 (100) | 5 (38.5) | <.001 |
| Death | 7 (14) | 0 (0) | 0 (0) | 7 (53.8) | <.001 |
Significant values are shown in bold.
Abbreviations: COVID-19, coronavirus 2019.